Omron Launches Sleep Monitor With ResMed Technology

SAN DIEGO, May 23, 2012 - The Omron Sleep Design HSL-101 offers wireless sleep monitoring and connection to Wellness Link - ResMed Inc. (NYSE:RMD) announced the launch of the first product in Japan using technology from its recently acquired company, BiancaMed. The product, launched by BiancaMed partner Omron Healthcare, is a new wireless sleep monitoring device. The Omron Sleep Design HSL-101 is part of a new strategy by Omron, named "All for Healthcare."

How Omron Sleep Design Works

The device uses ResMed technology to offer wireless, non-contact sleep monitoring which in turn connects to health care support services in Japan. To use the Omron Sleep Design HSL-101, a patient places the device beside the bed. With ResMed's non-contact sensing technology, the device measures sleep throughout the night and can report key sleep quality metrics, such as sleep onset time and total sleep time. In the morning, users can generate a full report on the night's sleep with the push of a button. When the data is connected to the cloud as part of Omron's Wellness Link service, a full picture of sleep health is provided, alongside a customized summary of health tips and advice... ResMed's Press Release -

ResMed : Acquisition of BiancaMed

July 6, 2011 - ResMed Inc. (NYSE: RMD and ASX: RMD), a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders, announced that it has acquired BiancaMed Ltd., a leading Irish medical technology company. ResMed purchased all of BiancaMed's outstanding shares with cash.

BiancaMed has developed and is marketing an innovative, convenient, non-contact device to monitor sleep and breathing in the home and hospital. BiancaMed's SleepMinder(TM) is an accurate, touch-free device that measures sleep and breathing with sophisticated biometric software. The core of BiancaMed's proprietary technology is a motion sensor that can detect respiration and movement without physical contact with the human body. The company is developing a number of other applications for the technology, across a range of medical and consumer settings.

BiancaMed will become a part of ResMed's newly-created Ventures and Initiatives unit. ResMed estimates the acquisition will dilute ResMed's earnings per share by approximately $0.04 in fiscal year 2012, excluding amortization of intangibles and one-time acquisition related costs... ResMed's Press Release - [PDF] BiancaMed's Press Release -

ResMed : New iPhone App

May 24, 2011 - Are you always tired? Examine your risk of sleep apnea with ResMed's Sleep Assessment app for iPhone® or iPod Touch® - ResMed (NYSE: RMD) released the ResMed Sleep Assessment app, a novel new app for iPhone that lets users record themselves during sleep. The app also includes a clinically validated questionnaire that assesses their risk and other helpful features to empower users to discuss their sleep health with their physician.

Excessive tiredness may be due to sleep apnea

Feeling excessively tired or fatigued is often the result of disrupted, unhealthy sleep. Numerous factors can lead to poor quality sleep, some of which have significant negative health effects. One possible cause of fatigue is sleep apnea, a common sleep disorder. People with sleep apnea report feeling like they're living in a fog, and that no matter how much they sleep they still feel exhausted.
Sleep apnea is a serious health condition in which a person stops breathing temporarily during sleep. After several seconds, the brain triggers a wake-up response, causing the person to awaken gasping. These events may happen hundreds of times per night, though the sleeper usually won't remember waking up. Often a spouse or partner will notice that the person snores loudly during sleep.
Sleep apnea affects approximately one in five U.S. adults, although it is estimated that as many as 80% of sleep apnea sufferers are undiagnosed and untreated.(1) A known cause of hypertension, untreated sleep apnea has also been linked with type 2 diabetes, cardiovascular disease, depression and stroke.(2-6) People who have sleep apnea feel chronically fatigued and may experience a variety of other symptoms, such as headaches, difficulty concentrating and irritability, to name just a few. Additionally, the loud snoring of sleep apnea can be disruptive to relationships, wreaking equal havoc on a spouse or partner's quality of sleep...


...ResMed's Sleep Assessment app combines a clinically validated questionnaire that quantifies a person's risk of sleep apnea based on known characteristics with an overnight snore recorder that lets them compare their snoring to the snoring of an actual sleep apnea patient. With the snore recorder feature, the user simply starts the app and sets their device by their bedside before sleep. The device records them throughout the night. Users can play back their recording and compare it to sample recordings from actual sleep apnea patients. They may also refer to their recording and questionnaire results when speaking with a physician about their sleep concerns.
In addition to the snore recorder and questionnaire, ResMed's Sleep Assessment app also includes a Sleep Lab Locator, which helps users find a sleep center in their area. Additionally, the app includes a "Sounds to Sleep By" feature with recordings of soothing sounds to play while drifting off to sleep... ResMed's Press Release -

ResMed : Study Shows its New CPAP Device Increases Patient Compliance

Sept 16, 2010 - Clinical study confirms new features of S9 Series prolong patients' sleep by up to 30 minutes - ResMed (NYSE: RMD), a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment announced the results of a clinical study confirming that patients' compliance with sleep therapy increases when using ResMed's new CPAP device.
The clinical study of 50 patients suffering from sleep apnoea showed an improvement of 30 minutes in average daily usage, from a mean of 6 hours 35 minutes on the patient's usual CPAP device, to 7 hours 5 minutes, when using the new S9 Series.
Sleep apnoea is one of the more common, and yet highly undiagnosed, sleep disorders. Obstructive sleep apnoea (OSA) is the most common type of sleep apnoea and is marked by the collapse or obstruction of the airway during sleep. The most effective treatment is Continuous Positive Airway Pressure (CPAP) therapy. In this non-invasive treatment, air is pressurised by a small device and delivered to the airway of the patient through a mask that fits on/over the nose, or nose and mouth. The pressurised air keeps the upper airway open and helps the person to get a restful night without interruptions caused by apnoeas... ResMed's Press Release -

ResMed : Next-Generation CPAP Series in Europe

Feb 22, 2010- The S9 Series Offers More Comfort & Sleek Design; New CPAP Expected to Increase Patient Compliance - ResMed (NYSE:RMD), a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes. The S9 Series is expected to help more sleep apnoea patients adhere to the treatment, but also help sleep professionals make more informed decisions.

The most effective treatment for sleep apnoea is Continuous Positive Airway Pressure (CPAP) therapy. In this non-invasive treatment, air is pressurised by a small device and delivered to the airway of the patient through a mask that fits on/over the nose, or nose and mouth. The pressurised air keeps the upper airway open and helps the person to get a restful night without interruptions caused by apnoeas.

"With patients across the world in mind, we are thrilled to introduce a true revolution in positive airway pressure therapy," ... ResMed's Press Release -

ResMed : Laboratoires Narval Acquisition

Oct. 5 - 2009 - ResMed Inc. (NYSE: RMD), a leading developer, manufacturer and distributor of sleep and respiratory medical equipment, announced that it has acquired Laboratoires Narval. Based in France, Laboratoires Narval manufactures and distributes the Narval O.R.M.(TM), an innovative mandibular repositioning device (MRD) that offers a solution to patients for snoring and obstructive sleep apnea (OSA), especially for those with mild OSA.

With this acquisition, ResMed adds another therapy to supplement its existing positive airway pressure-based solutions, providing a broader offering for this patient group. ResMed plans to commercialize this device in selected European markets... ResMed's Press Release -

SleepQuest and ResMed : Latest Sleep Disorder Technology Tested

August 28, 2008 - SleepQuest has partnered with ResMed, a leading manufacturer of medical equipment for sleep-disordered breathing, to conduct clinical trials of a new wireless technology used to monitor patients with Obstructive Sleep Apnea from wherever they are sleeping.
The technology is intended to more easily provide data that can be used to improve the quality of care for those requiring PAP treatment... SleepQuest's Press Release -

ResMed and LifeScan : Co-Marketing Agreement Focused on Treatment of Type 2 Diabetes and Sleep-Disordered Breathing

June 10, 2008 – LifeScan, Inc., maker of the leading OneTouch® Brand of blood glucose meters for people with diabetes, and ResMed, Inc. (NYSE: RMD), a leading manufacturer of medical devices for the diagnosis and treatment of sleep apnea, today announced an exclusive co-marketing agreement designed to improve the lives of people with type 2 diabetes and sleep-disordered breathing (SDB). The joint work of the two companies will focus on educational and cross-promotional efforts intended to benefit the patients and healthcare professionals served by both companies.

The goal is to build awareness among healthcare professionals of the overlap of these two conditions, trigger new approaches to patient care, and ultimately improve the rate of treating patients suffering from both SDB and diabetes... LifeScan's Press Release -